Get started
BIOLINE RXBIOLINE RXBIOLINE RX

BIOLINE RX

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BLRX chart


Full chart

BLRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪151.18 M‬ ILS
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1 ILS
Net income (FY)
‪−223.55 M‬ ILS
Revenue (FY)
‪17.70 M‬ ILS
Shares float
‪1.09 B‬
Beta (1Y)
1.19

Employees


Employees (FY)
38
Change (1Y)
−11 −22.45%
Revenue / Employee (1Y)
‪128.30 K‬ ILS
Net income / Employee (1Y)
‪−1.62 M‬ ILS

About BIOLINE RX


Sector
Health Technology
CEO
Philip Adam Serlin
Headquarters
Modi'in
Website
biolinerx.com
Founded
2003
ISIN
IL0011015182
FIGI
BBG000D3FWW6
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BLRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BLRX is 11.6 ILA — it has increased by 10.32% in the past 24 hours. Watch BIOLINE RX stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange BIOLINE RX stocks are traded under the ticker BLRX.
BLRX stock has risen by 13.01% compared to the previous week, the month change is a 3.73% rise, over the last year BIOLINE RX has showed a −71.14% decrease.
We've gathered analysts' opinions on BIOLINE RX future price: according to them, BLRX price has a max estimate of 528.67 ILA and a min estimate of 50.35 ILA. Watch BLRX chart and read a more detailed BIOLINE RX stock forecast: see what analysts think of BIOLINE RX and suggest that you do with its stocks.
BLRX reached its all-time high on Oct 19, 2009 with the price of 5,898.0 ILA, and its all-time low was 11.6 ILA and was reached on Oct 31, 2024. View more price dynamics on BLRX chart.
See other stocks reaching their highest and lowest prices.
BLRX stock is 19.83% volatile and has beta coefficient of 1.19. Track BIOLINE RX stock price on the chart and check out the list of the most volatile stocks — is BIOLINE RX there?
Today BIOLINE RX has the market capitalization of ‪166.78 M‬, it has increased by 12.10% over the last week.
Yes, you can track BIOLINE RX financials in yearly and quarterly reports right on TradingView.
BIOLINE RX is going to release the next earnings report on Nov 25, 2024. Keep track of upcoming events with our Earnings Calendar.
BIOLINE RX revenue for the last quarter amounts to ‪20.38 M‬ ILA, despite the estimated figure of ‪14.85 M‬ ILA. In the next quarter, revenue is expected to reach ‪19.74 M‬ ILA.
BLRX net income for the last quarter is ‪1.80 M‬ ILS, while the quarter before that showed ‪−2.55 M‬ ILS of net income which accounts for 170.72% change. Track more BIOLINE RX financial stats to get the full picture.
No, BLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 38.00 employees. See our rating of the largest employees — is BIOLINE RX on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOLINE RX EBITDA is ‪−122.17 M‬ ILS, and current EBITDA margin is −866.81%. See more stats in BIOLINE RX financial statements.
Like other stocks, BLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOLINE RX stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOLINE RX technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOLINE RX stock shows the strong sell signal. See more of BIOLINE RX technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.